Paclitaxin (Paclitaxel)

Paclitaxel, the active ingredient in Paclitaxin, is a taxane presented as a  strength/form  for epidural use. It treats various oncologic indications and is administered to adult cancer patients. GNH USA supplies Paclitaxin as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Paclitaxin as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Paclitaxel is a chemotherapy agent used in several solid‑tumor treatment pathways.

- Breast cancer: improves survival by inhibiting tumor cell proliferation. - Ovarian cancer: used after surgery to reduce recurrence risk. - Non‑small cell lung cancer: administered to extend progression‑free survival. - Kaposi's sarcoma: controls disease spread in immunocompromised patients. - Gastric cancer: part of combination regimens to shrink tumors. - Pancreatic cancer: used in advanced disease protocols.

Paclitaxel may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white‑blood‑cell count increasing infection risk. - Alopecia: hair loss affecting scalp and body hair. - Peripheral neuropathy: tingling or numbness in extremities. - Nausea and vomiting: gastrointestinal upset. - Fatigue: generalized tiredness. - Myalgia: muscle aches.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis‑like symptoms. - Cardiotoxicity: arrhythmias or reduced heart function. - Severe neutropenic fever: life‑threatening infection. - Pulmonary toxicity: interstitial pneumonitis. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary malignancies: rare therapy‑related cancers.

When using Paclitaxin, clinicians should observe several safety measures.

- Monitor blood counts: perform regular CBC with differential to detect neutropenia. - Assess neuropathy: evaluate sensory changes before each dose. - Pre‑medicate: give antihistamines and corticosteroids to reduce hypersensitivity risk. - Review cardiac function: baseline ECG and periodic monitoring for arrhythmias. - Adjust for hepatic impairment: consider dose modification in patients with liver dysfunction. - Store at ambient temperature: keep in original container, protect from moisture and light.

Paclitaxin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase paclitaxel exposure. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce paclitaxel levels. - Concurrent use of other neurotoxic agents (e.g., vincristine): heighten neuropathy risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding tendency.\n- Live vaccines: immunosuppression may diminish vaccine efficacy.

- Strong acid‑reducing agents: potential alteration of absorption when oral formulations are used.